Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 22, 2019 07:30 ET | Source: Biogen Inc.

Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate)

CAMBRIDGE, Mass., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced detailed results from the Phase 3 EVOLVE-MS-2 study demonstrating the improved patient-assessed...
September 11, 2019 05:00 ET | Source: Biogen Inc.

New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years

TECFIDERA consistently maintained low levels of disease activity with no increased risk in adverse events over a decade of treatmentLatest interim data from Phase 3 EVOLVE-MS-1 trial show Biogen and...
May 30, 2019 07:30 ET | Source: Biogen Inc.

New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis

Diroximel fumarate significantly reduced disease activity in newly diagnosed relapsing multiple sclerosis (MS) patients and those previously treated with interferons or glatiramer acetate Data show...
May 01, 2019 07:30 ET | Source: Biogen Inc.

Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases

Data demonstrate that pre-symptomatic infants with SMA treated with SPINRAZA® (nusinersen) over three years achieved motor milestones that are more consistent with normal childhood...
February 25, 2019 07:30 ET | Source: Biogen Inc.

Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis

DUBLIN, Ireland and CAMBRIDGE, Mass., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA)...